Immunomedics Reports High Efficacy for Epratuzumab Phase II
By Catherine Shaffer
Wednesday, August 14, 2013
Immunomedics Inc.'s epratuzumab exceeded expectations in a Phase II trial in follicular lymphoma, producing a response rate of 88.2 percent when used in combination with rituximab.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.